Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1167-3521 | Other Identifier | WHO | |
| jRCT1080222785 | Registry Identifier | jRCT | |
| UMIN000016782 | Registry Identifier | UMIN Clinical Trials Registry |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate biomarkers which may be predictors of efficacy and safety of treatment with mFOLFOX6 + bevacizumab versus mFOLFOX6 + panitumumab therapy in patients with chemotherapy-naïve unresectable advanced or recurrent colorectal cancer.
The drug being tested in this study is called Panitumumab. This exploratory study will investigate biomarkers which may be predictors of efficacy and safety of treatment with mFOLFOX6 + bevacizumab versus mFOLFOX6 + panitumumab therapy in patients with chemotherapy-naïve unresectable advanced or recurrent colorectal cancer.
Tumor tissue samples obtained from the participants who enrolled in the safety/efficacy study of Panitumumab + mFOLFOX versus bevacizumab + mFOLFOX (PARADIGM Study: NCT02394795) and provided consent for this additional study will be used. Mutations, amplification and rearrangement of predefined tumor-associated genes will be investigated using DNA collected from tumor samples used for assessing RAS mutations and plasma free DNA collected before administration of cycle 1 and at the discontinuation of the protocol treatment in the main study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group P; mFOLFOX6 + panitumumab combination therapy | OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks |
| |
| Group B; mFOLFOX6 + bevacizumab combination therapy | OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab | Drug | oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival (OS) | OS obtained in the main study will be stratified by the presence or absence of mutation of tumor-associated genes in tumor tissues at the baseline of the main study to evaluate the relationship between OS and gene mutations. OS will be measured as the time from the date of randomization to the date of death due to any causes. | Up to approximately 63 months |
| Measure | Description | Time Frame |
|---|---|---|
| Progression-Free Survival (PFS) | PFS obtained in the main study will be stratified by the presence or absence of mutation of tumor-associated genes in tumor tissues at the baseline of the main study to evaluate the relationship between the efficacy endpoint and gene mutations. PFS is defined as the time from the date of randomization to the earlier of Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or death due to any cause. |
Not provided
Inclusion Criteria:
(1) Patients who are enrolled in the main study and personally provided written consent after adequately explained about the contents of the additional study
Exclusion Criteria:
(1) Patients who are determined by the investigator or researchers to be not suitable for participating in the additional study
Not provided
Not provided
Patients who are enrolled in the main study and personally provided written consent after adequately explained about the contents of the additional study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Study Director | Takeda | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ichinomiya | Aichi-ken | Japan | ||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38347302 | Derived | Shitara K, Muro K, Watanabe J, Yamazaki K, Ohori H, Shiozawa M, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Mori I, Yamanaka K, Hihara M, Soeda J, Misumi T, Yamamoto K, Yamashita R, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer. Nat Med. 2024 Mar;30(3):730-739. doi: 10.1038/s41591-023-02791-w. Epub 2024 Feb 12. | |
| 28237539 |
| Label | URL |
|---|---|
| Click here for more information about this trial in easy-to-understand language, including a Plain Language Summary of the results if the trial has been completed. | View source |
Not provided
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Not provided
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Not provided
Not provided
Not provided
Not provided
| oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab | Drug | oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion |
|
| Up to approximately 63 months |
| Response Rate (RR) | RR obtained in the main study will be stratified by the presence or absence of mutation of tumor-associated genes in tumor tissues at the baseline of the main study to evaluate the relationship between the efficacy endpoint and gene mutations. RR is defined as percentage of participants who achieve Complete Response (CR) and Partial Response (PR) as the best overall response per RECIST version 1.1. | Approximately 12 months |
| Duration of Response (DOR) | DOR obtained in the main study will be stratified by the presence or absence of mutation of tumor-associated genes in tumor tissues at the baseline of the main study to evaluate the relationship between the efficacy endpoint and gene mutations. DOR means that the period from the day when either CR or PR is first confirmed until the day of documented PD or the day of death due to all causes, whichever occurs earlier. | Up to approximately 63 months |
| Percentage of Participants who Proceeded to Surgical Resection | The outcome obtained in the main study will be stratified by the presence or absence of mutation of tumor-associated genes in tumor tissues at the baseline of the main study to evaluate the relationship between the efficacy endpoint and gene mutations. | Up to approximately 63 month |
| Percentage of Participants with Early Tumor Shrinkage | The outcome obtained in the main study will be stratified by the presence or absence of mutation of tumor-associated genes in tumor tissues at the baseline of the main study to evaluate the relationship between the efficacy endpoint and gene mutations. | Up to approximately 63 months |
| Degree of the Maximum Tumor Shrinkage (Depth of Response) | The outcome obtained in the main study will be stratified by the presence or absence of mutation of tumor-associated genes in tumor tissues at the baseline of the main study to evaluate the relationship between the efficacy endpoint and gene mutations. | Up to approximately 63 months |
| Evaluation of the Relationship of Each Biomarker in Plasma Free DNA and Tumor Samples at Baseline of the Main Study | Up to approximately 63 months |
| Evaluation of the Relationship between Each Biomarker in Plasma Free DNA at Baseline of the Main Study, and Efficacy Endpoints | Up to approximately 63 months |
| Evaluation of the Relationship between a Change in Each Biomarker in Plasma Free DNA at Baseline and the Discontinuation of the Protocol Treatment of the Main Study, and Efficacy Endpoints | Up to approximately 63 months |
| Evaluation of the Relationship between a Change in Each Biomarker in Tumor Tissue at Baseline and the Discontinuation of the Protocol Treatment of the Main Study, and Efficacy Endpoints | Up to approximately 63 months |
| Komaki |
| Aichi-ken |
| Japan |
| Kounan | Aichi-ken | Japan |
| Nagakute | Aichi-ken | Japan |
| Nagoya | Aichi-ken | Japan |
| Okazaki | Aichi-ken | Japan |
| Toyohashi | Aichi-ken | Japan |
| Toyokawa | Aichi-ken | Japan |
| Toyota | Aichi-ken | Japan |
| Yatomi | Aichi-ken | Japan |
| Daisen | Akita | Japan |
| Hirosaki | Aomori | Japan |
| Misawa | Aomori | Japan |
| Kashiwa | Chiba | Japan |
| Yachiyo | Chiba | Japan |
| Matsuyama | Ehime | Japan |
| Tōon | Ehime | Japan |
| Tsuruga | Fukui | Japan |
| Yoshida | Fukui | Japan |
| Kitakyushu | Fukuoka | Japan |
| Koga | Fukuoka | Japan |
| Koga | Fukuoka | Japan |
| Kurume | Fukuoka | Japan |
| Omuta | Fukuoka | Japan |
| Aizu-Wakamatsu | Fukushima | Japan |
| Iwaki | Fukushima | Japan |
| Kōriyama | Fukushima | Japan |
| Shirakawa | Fukushima | Japan |
| Hashima | Gifu | Japan |
| Kakamigahara | Gifu | Japan |
| Minokamo | Gifu | Japan |
| Okazai | Gifu | Japan |
| Ōgaki | Gifu | Japan |
| Maebashi | Gunma | Japan |
| Ōta | Gunma | Japan |
| Fukuyama | Hiroshima | Japan |
| Hakodate | Hokkaido | Japan |
| Kitami | Hokkaido | Japan |
| Kushiro | Hokkaido | Japan |
| Obihiro | Hokkaido | Japan |
| Otaru | Hokkaido | Japan |
| Sapporo | Hokkaido | Japan |
| Akashi | Hyōgo | Japan |
| Amagasaki | Hyōgo | Japan |
| Himeji | Hyōgo | Japan |
| Kobe | Hyōgo | Japan |
| Nishinomiya | Hyōgo | Japan |
| Hitachi | Ibaraki | Japan |
| Kasama | Ibaraki | Japan |
| Ryūgasaki | Ibaraki | Japan |
| Tsuchiura | Ibaraki | Japan |
| Tsukuba | Ibaraki | Japan |
| Hakusan | Ishikawa-ken | Japan |
| Kaga | Ishikawa-ken | Japan |
| Kahoku | Ishikawa-ken | Japan |
| Kanazawa | Ishikawa-ken | Japan |
| Nanao | Ishikawa-ken | Japan |
| Morioka | Iwate | Japan |
| Kida | Kagawa-ken | Japan |
| Marugame | Kagawa-ken | Japan |
| Takamatsu | Kagawa-ken | Japan |
| Fujisawa | Kanagawa | Japan |
| Hiratsuka | Kanagawa | Japan |
| Isehara | Kanagawa | Japan |
| Kamakura | Kanagawa | Japan |
| Kanazawachō | Kanagawa | Japan |
| Sagamihara | Kanagawa | Japan |
| Yokohama | Kanagawa | Japan |
| Yokosuka | Kanagawa | Japan |
| Nankoku | Kochi | Japan |
| Matsuzaka | Mie-ken | Japan |
| Tsu | Mie-ken | Japan |
| Yokkaichi | Mie-ken | Japan |
| Ishinomaki | Miyagi | Japan |
| Murata | Miyagi | Japan |
| Natori-shi | Miyagi | Japan |
| Ōsaki | Miyagi | Japan |
| Sendai | Miyagi | Japan |
| Matsumoto | Nagano | Japan |
| Saku | Nagano | Japan |
| Ōmura | Nagasaki | Japan |
| Sasebo | Nagasaki | Japan |
| Ikoma | Nara | Japan |
| Tenri | Nara | Japan |
| Yamatotakada | Nara | Japan |
| Yufu | Oita Prefecture | Japan |
| Kurashiki | Okayama-ken | Japan |
| Naha | Okinawa | Japan |
| Tomigusuku | Okinawa | Japan |
| Urasoe | Okinawa | Japan |
| Hirakata | Osaka | Japan |
| Kawachi-Nagano | Osaka | Japan |
| Moriguchi | Osaka | Japan |
| Neyagawa | Osaka | Japan |
| Sayama | Osaka | Japan |
| Suita | Osaka | Japan |
| Takatsuki | Osaka | Japan |
| Kawagoe | Saitama | Japan |
| Kitaadachi | Saitama | Japan |
| Koshigaya | Saitama | Japan |
| Moriyama | Shiga | Japan |
| Ōtsu | Shiga | Japan |
| Izumi | Shimane | Japan |
| Izumo | Shimane | Japan |
| Hamamatsu | Shizuoka | Japan |
| Izunokuni | Shizuoka | Japan |
| Sunto | Shizuoka | Japan |
| Shimotsuga | Tochigi | Japan |
| Shimotsuke | Tochigi | Japan |
| Utsunomiya | Tochigi | Japan |
| Komatsushimachō | Tokushima | Japan |
| Bunkyo-ku | Tokyo | Japan |
| Chiyoda-ku | Tokyo | Japan |
| Chuo-ku | Tokyo | Japan |
| Itabashi-ku | Tokyo | Japan |
| Koto-ku | Tokyo | Japan |
| Machida | Tokyo | Japan |
| Minato-ku | Tokyo | Japan |
| Musashino | Tokyo | Japan |
| Shinagawa-ku | Tokyo | Japan |
| Shinjyuku-ku | Tokyo | Japan |
| Yonago | Tottori | Japan |
| Kurobe-shi | Toyama | Japan |
| Takaoka | Toyama | Japan |
| Sakata | Yamagata | Japan |
| Tsuruoka | Yamagata | Japan |
| Iwakuni | Yamaguchi | Japan |
| Kofu | Yamanashi | Japan |
| Akita | Japan |
| Aomori | Japan |
| Chiba | Japan |
| Fukui | Japan |
| Fukuoka | Japan |
| Gifu | Japan |
| Kagoshima | Japan |
| Kochi | Japan |
| Kumamoto | Japan |
| Kyoto | Japan |
| Miyazaki | Japan |
| Nagano | Japan |
| Nagasaki | Japan |
| Niigata | Japan |
| Okayama | Japan |
| Okinawa | Japan |
| Osaka | Japan |
| Saga | Japan |
| Saitama | Japan |
| Shizuoka | Japan |
| Tokushima | Japan |
| Toyama | Japan |
| Yamagata | Japan |
| Derived |
| Yoshino T, Uetake H, Tsuchihara K, Shitara K, Yamazaki K, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Yamanaka K, Iwasaki K, Soeda J, Hihara M, Yamanaka T, Ochiai A, Muro K. Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naive Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2017 Jun;16(2):158-163. doi: 10.1016/j.clcc.2017.01.001. Epub 2017 Jan 24. |
| Click here to ask Takeda's chatbot for comprehensive and easy-to-understand information about clinical trials - even across products and indications - in your local language. | View source |
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077150 | Oxaliplatin |
| D005472 | Fluorouracil |
| D000077544 | Panitumumab |
| D000068258 | Bevacizumab |
| ID | Term |
|---|---|
| D056831 | Coordination Complexes |
| D009930 | Organic Chemicals |
| D014498 | Uracil |
| D011744 | Pyrimidinones |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided